BridgeBio Pharma (Nasdaq: BBIO) announced the publication of post-hoc analyses in Circulation: Heart Failure examining kidney function in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis, its approved TTR-stabilizing drug.

The analyses, drawn from Phase 2 and Phase 3 (ATTRibute-CM) randomized, double-blind, placebo-controlled trials, found that acoramidis initiation was associated with an early, reversible estimated glomerular filtration rate (eGFR) dip of 8.5 mL/min/1.73 m², alongside a placebo-corrected 15.5% reduction in urinary albumin-to-creatinine ratio (UACR) by Day 28 (P<0.05). No kidney-related adverse events were observed in these analyses.

Through Month 30, patients treated with acoramidis showed a sustained improvement in chronic eGFR slope of +2.47 mL/min/1.73 m² per year (p<0.001) and a sustained 13.7% UACR reduction (p=0.026). The analyses noted this pattern resembles that seen with drugs acting directly on the kidney, such as ACE inhibitors, ARBs, and SGLT2 inhibitors.

Patients with eGFR dips larger than the overall population median experienced a 58% lower risk of death or cardiovascular hospitalization (HR: 0.42; 95% CI, 0.22–0.78; P=0.006) and a 66% lower risk of hospitalization alone (HR: 0.34; 95% CI, 0.17–0.66; P=0.002) in the first year of treatment.

"Acoramidis appears to have a protective effect on the heart and the kidney simultaneously, with potentially meaningful implications for long-term survival and reduced cardiovascular hospitalizations," said Professor Jeffrey Testani, M.D., M.T.R. of Yale School of Medicine and first author of the publication.

Acoramidis is approved in the U.S. as Attruby and in Europe as Beyonttra, among other markets, for the treatment of ATTR-CM in adults to reduce cardiovascular death and cardiovascular-related hospitalization. The kidney findings are based on post-hoc analyses, which the company acknowledged may not be predictive of future clinical outcomes.